S-L 11.14: a monoclonal antibody recognizing neuroectodermal tumors with possible value for bone marrow purging before autograft.
A new monoclonal antibody (S-L 11.14) raised against small cell lung cancer reacted with all but one neuroblastoma tumor cell sample tested and was relatively specific for such cells within the bone marrow. The ability of S-L 11.14 to eliminate neuroblastoma cells from the bone marrow with an immunomagnetic purging method was evaluated in an experimental model using the LAN.1 and SKNBE neuroblastoma cell lines as targets. Residual malignant cells after the purging procedure were quantified by the Hoechst staining method. The use of S-L 11.14 as a single reagent resulted in a 3-log elimination of malignant cells, a depletion equal to that obtained with a cocktail of five monoclonal antibodies currently used in clinical trials. The addition of the S-L 11.14 antibody to this cocktail did not enhance depletion.
Combaret
V
V
Bone Marrow Transplantation Unit, Centre Léon Bérard, Lyon, France.
Kremens
B
B
Favrot
M C
MC
Laurent
J C
JC
Philip
T
T
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D018288:Carcinoma, Small Cell / Q000276:immunology; D003114:Colony-Forming Units Assay; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology; D009447:Neuroblastoma / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm